The DOI matches its Crossref record.
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations
Abstract
BACKGROUND: Rifampin (rifampicin) is a potent inducer of several cytochrome P450 (CYP) enzymes, including CYP3A4. The cholesterol-lowering drug simvastatin has an extensive first-pass metabolism, and it is partially metabolized by CYP3A4. This study was conducted to investigate the effect of rifampin on the pharmacokinetics of simvastatin. METHODS: In a randomized cross-over study with two phases and a washout of 4 weeks, 10 healthy volunteers received a 5-day pretreatment with rifampin (600 mg daily) or placebo. On day 6, a single 40-mg dose of simvastatin was administered orally. Plasma concentrations of simvastatin and its active metabolite simvastatin acid were measured up to 12 hours with a sensitive liquid chromatography-ion spray tandem mass spectrometry method. RESULTS: Rifampin decreased the total area under the plasma concentration-time curve of simvastatin and simvastatin acid by 87% (P < .001) and 93% (P < .001), respectively. Also the peak concentrations of both simvastatin and simvastatin acid were reduced greatly (by 90%) by rifampin (P < .001). On the other hand, rifampin had no significant effect on the elimination half-life of simvastatin or simvastatin acid. CONCLUSIONS: Rifampin greatly decreases the plasma concentrations of simvastatin and simvastatin acid. Because the elimination half-life of simvastatin was not affected by rifampin, induction of the CYP3A4-mediated first-pass metabolism of simvastatin in the intestine and the liver probably explains this interaction. Concomitant use of potent inducers of CYP3A4 can lead to a considerably reduced cholesterol-lowering efficacy of simvastatin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Niemi, M., Pasanen, M. K., & Neuvonen, P. J. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002857 · Cited by 633
Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 576
The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group
Koziolek, M., Alcaro, S., Augustijns, P., Basit, A. W., Grimm, M., Hens, B., Hoad, C. L., Jedamzik, P., Madla, C. M., Maliepaard, M., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.04.003 · Cited by 385
Kasiske, B., Cosio, F. G., Beto, J., Bolton, K., Chavers, B. M., Grimm, R., Levin, A., Masri, B., Parekh, R., Wanner, C., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6135.2004.0355.x · Cited by 316
Chen, J., & Raymond, K. (2006) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/1476-0711-5-3 · Cited by 296
Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist
Dingemanse, J., & van Giersbergen, P. L. M. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443150-00003 · Cited by 272
Schmitt, C., Kuhn, B., Zhang, X., Kivitz, A. J., & Grange, S. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.35 · Cited by 257
Statin drug interactions and related adverse reactions
Bellosta, S., & Corsini, A. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.712959 · Cited by 111
Almond, L. M., Mukadam, S., Gardner, I., Okialda, K., Wong, S., Hatley, O., Tay, S., Rowland-Yeo, K., Jamei, M., Rostami-Hodjegan, A., et al. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066845 · Cited by 101
Bergman, A. J., Murphy, G., Burke, J., Zhao, J. J., Valesky, R., Liu, L., Lasseter, K. C., He, W., Prueksaritanont, T., Qiu, Y., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004268044 · Cited by 97
Bolhuis, M. S., Panday, P. N., Pranger, A. D., Kosterink, J. G. W., & Alffenaar, J.-W. C. (2011) · Pharmaceutics · doi:10.3390/pharmaceutics3040865 · Cited by 62
Consideraciones específicas en la prescripción e intercambio terapéutico de estatinas
García-Sabina, A., Gulín-Dávila, J., Sempere-Serrano, P., González-Juanatey, C., & Martínez-Pacheco, R. (2012) · Farmacia Hospitalaria · doi:10.1016/j.farma.2011.02.010 · Cited by 17
Spanakis, M., Alon-Ellenbogen, D., Ioannou, P., & Spernovasilis, N. (2023) · Pharmacy · doi:10.3390/pharmacy11040130 · Cited by 3
Metadata
- Authors
- Kyrklund, C.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2000-12
- Volume
- 68
- Issue
- 6
- Pages
- 592-597
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2039613248
- Cited by
- 163
- References
- 0
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.